Preclinical characterization and phase 1 clinical testing of targeting mitochondrial peroxiredoxin 3 in cancer

Victoria Gibson, Joanna Dzialo, Terri Messier, Aleksandra Bzura, Charlotte Poile, Jan Rogel, Jens C. Hahne, Aida Habibovic, Stephanie Stead, Alexis Saaman, Kevin G. Blyth, Peter W. Szlosarek, Simon Lord, Fiona Thistlethwaite, Min Zhang, Apostolos Nakas, Peter Wells-Jordan, Kudzayi Kutywayo, Kelly J. Butnor, Nicholas. H. Heintz, George N. Naumov, Maurice Dungey, Julio Herrero Colomina, Burak Aktas, Sean Dulloo, James Spicer, Dean A. Fennell, Brian Cunniff

Open source

DOI: 10.1038/s41467-026-75153-y
Published: 2026-07-14
Container: Nature Communications
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41467-026-75153-y,
  title = {Preclinical characterization and phase 1 clinical testing of targeting mitochondrial peroxiredoxin 3 in cancer},
  author = {Victoria Gibson and Joanna Dzialo and Terri Messier and Aleksandra Bzura and Charlotte Poile and Jan Rogel and Jens C. Hahne and Aida Habibovic and Stephanie Stead and Alexis Saaman and Kevin G. Blyth and Peter W. Szlosarek and Simon Lord and Fiona Thistlethwaite and Min Zhang and Apostolos Nakas and Peter Wells-Jordan and Kudzayi Kutywayo and Kelly J. Butnor and Nicholas. H. Heintz and George N. Naumov and Maurice Dungey and Julio Herrero Colomina and Burak Aktas and Sean Dulloo and James Spicer and Dean A. Fennell and Brian Cunniff},
  year = {2026},
  journal = {Nature Communications},
  doi = {10.1038/s41467-026-75153-y},
  url = {https://doi.org/10.1038/s41467-026-75153-y}
}

RIS

TY  - JOUR
TI  - Preclinical characterization and phase 1 clinical testing of targeting mitochondrial peroxiredoxin 3 in cancer
AU  - Victoria Gibson
AU  - Joanna Dzialo
AU  - Terri Messier
AU  - Aleksandra Bzura
AU  - Charlotte Poile
AU  - Jan Rogel
AU  - Jens C. Hahne
AU  - Aida Habibovic
AU  - Stephanie Stead
AU  - Alexis Saaman
AU  - Kevin G. Blyth
AU  - Peter W. Szlosarek
AU  - Simon Lord
AU  - Fiona Thistlethwaite
AU  - Min Zhang
AU  - Apostolos Nakas
AU  - Peter Wells-Jordan
AU  - Kudzayi Kutywayo
AU  - Kelly J. Butnor
AU  - Nicholas. H. Heintz
AU  - George N. Naumov
AU  - Maurice Dungey
AU  - Julio Herrero Colomina
AU  - Burak Aktas
AU  - Sean Dulloo
AU  - James Spicer
AU  - Dean A. Fennell
AU  - Brian Cunniff
PY  - 2026
JO  - Nature Communications
DO  - 10.1038/s41467-026-75153-y
UR  - https://doi.org/10.1038/s41467-026-75153-y
ER  -

APA

Gibson, V., Dzialo, J., Messier, T., Bzura, A., Poile, C., Rogel, J., Hahne, J. C., Habibovic, A., Stead, S., Saaman, A., Blyth, K. G., Szlosarek, P. W., Lord, S., Thistlethwaite, F., Zhang, M., Nakas, A., Wells-Jordan, P., Kutywayo, K., Butnor, K. J., Heintz, N. H., Naumov, G. N., Dungey, M., Colomina, J. H., Aktas, B., Dulloo, S., Spicer, J., Fennell, D. A., & Cunniff, B. (2026). Preclinical characterization and phase 1 clinical testing of targeting mitochondrial peroxiredoxin 3 in cancer. Nature Communications. https://doi.org/10.1038/s41467-026-75153-y

Source records

crossref · retrieved 2026-09-26T04:00:58.528Z